Innovent Biologics, Inc. · HKEX:1801
Innovent Biologics — H1 2022 Earnings Presentation
32 slides from Innovent Biologics's earnings presentation, August 2022
Slide 1: Innovent 2022 Interim Results - Appendix Pipeline Overview
Innovent 2022 Interim Results Appendix - Pipeline Overview August, 2022
Slide 2: Robust Pipeline Across Novel Therapeutics – Oncology
Robust Pipeline Across Novel Therapeutics – Oncology 6 approved, 2 NDA, 4 in pivotal trials and 13 assets in clinical stage Status Pivotal Phase Products Target (s) Modality Therapeutic Area Rights Pre-clinical IND Approved Phase 1 Phase 2 NDA Launched 2 / Phase 3 TYVYT® (sintilimab injection） PD-1
Slide 3: Robust Pipeline Across Novel Therapeutics – Non-oncology
Robust Pipeline Across Novel Therapeutics – Non-oncology 1 approved, 1 NDA, 7 assets in clinical stage Status Pivotal Therapeutic Products Target (s) Modality Rights Pre-clinical IND Approved Phase 1 Phase 2 Phase 2 / NDA Launched Area Phase 3 SULINNO® (adalimumab injection) TNF-alpha Monoclonal ant
Slide 4: Select Pipeline - Oncology
Divider: 换一个自己做的 Select Pipeline - Oncology Section 1 Business Overview - 2021
Slide 5: Sintilimab (PD-1): Only PD-1 Inhibitor Approved in 1L of 5 Cancers
Sintilimab (PD-1): The Only PD-1 Inhibitor with NDA Approval in the First Line Treatment of 5 Major Types of Cancer 1L sqNSCLC 1L ESCC EGFRm nsqNSCLC 2021.06 sNDA Approval 2022.06 sNDA Approval 2021.12 sNDA Accepted 1L nsqNSCLC 1L HCC 1L GC 2021.02 sNDA Approval 2021.06 sNDA Approval 2022.06 sNDA Ap
Slide 6: Pemazyre® (Pemigatinib, IBI-375)
Pemazyre® (Pemigatinib, IBI-375) China First Approved Target Therapy to Fill the Unmet Medical Need for Cholangiocarcinoma Enzyme Inhibitory Activity of IBI-375 Development Plan IBI-375 • 2L mCCA (cholangiocarcinoma) - Approved in Taiwan market for 2L mCCA in 2021.06. Desired target activity - Appro
Slide 7: Olverembatinib (BCR-ABL TKI, IBI-348)
Olverembatinib (BCR-ABL TKI, IBI-348) China’s First Approved Third-generation BCR-ABL TKI Clinical Highlights Differentiated Advantages • IBI-348 shown highly and durably efficacious in heavily TKI-pretreated • IBI-348 is an oral third-generation BCR-ABL1 inhibitor designed for patients with T315I-m
Slide 8: Cyramza® (ramucirumab)
Cyramza®(ramucirumab) A VEGFR2 antagonist approved for five indications of NSCLC, GC, HCC and CRC globally Clinical Highlights Development Plan GC: RAINBOW-Asia (ASCO GI 2021) HCC: Chinese population analysis in REACH-2 (2020 CSCO) • Entered into multifaceted collaboration with Eli Lilly in 2022.03
Slide 9: IBI-123 (selpercatinib)
IBI-123 (selpercatinib) First-in-class selective RET inhibitor showing robust efficacy Clinical Highlights Differentiated Advantages Retsevmo ® global clinical trial data (LIBRETTO-001) • Ret(s)evmo® is a highly selective and potent, CNS active RET inhibitor that exhibits unprecedented strong and du
Slide 10: IBI-326 (BCMA CAR-T)
IBI-326 (BCMA CAR-T) Fully-human and Potentially First BCMA CAR-T approved in China Clinical Highlights (2022 EHA) Differentiated Advantage • Improved efficacy likely due to the lower binding affinity of BCMA CAR (facilitate serial triggering of CAR-T cell) and long-term persistence of CAR-T cells •
Slide 11: IBI-310 (CTLA-4)
IBI-310 (CTLA-4) Leading CTLA-4 Antibody in Combo with Sintilimab at Multiple Pivotal Studies in China Phase 1a/1b Safety Data (N=27) Development Program Overview Part B+C (1b): Part A (1a): IBI-310 • Cervical Melanoma subtypes IBI-310 + sintilimab N=10 - Ongoing Phase 2 trial in 2nd line and above
Slide 12: IBI-344 (Taletrectinib, ROS1/NTRK)
IBI-344 (Taletrectinib, ROS1/NTRK) Leading next-generation ROS1/NTRK at Pivotal Phase 2 Clinical Highlights (2022 ASCO) Phase 2 Data (Data cutoff date: 2022.02.23) A: Crizotinib naive pts: ORR 92.5%（62/67）DCR 95.6% (64/67) B: Crizotinib pre-treated pts: ORR 50% (19/38) DCR 78.9% (30/38) C: Brain met
Slide 13: IBI-376 (PI3Kδ)
IBI-376 (PI3Kδ) Potential Best-in-class PI3Kδ at Pivotal Stage IBI-376 Demonstrated a High Rate of Rapid and Durable Response in r/r FL and r/r MZL Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma in China (ASCO 2022, #7574)
Slide 14: IBI-126 (tusamitamab ravtansine)
IBI-126 (tusamitamab ravtansine) Global FIC and only Phase 3 Stage ADC Targeting CEACAM-5 Potential FIC ADC with humanized antibody of high selectivity for CEACAM5 • Potential FIC ADC with humanized antibody of high selectivity for CEACAM51 • — a cell-surface glycoprotein that is highly expressed on
Slide 15: IBI-110 (LAG3)
IBI-110 (LAG3) Highly Potent LAG3 mAb to Synergize with Sintilimab IBI-110 Preliminary PoC data Development Program Overview Phase Ib preliminary PoC data for sqNSCLC (ASCO 2022 #e21145) Phase Ib preliminary PoC data for GC (ASCO 2022 #e16097) • One of the most advanced LAG3 programs - Over 280 pati
Slide 16: IBI-351 (KRAS G12C)
IBI-351 (KRAS G12C) A Potential Best-in-class KRAS G12C Selective Inhibitor IBI-351 Potential in China First-Tier Development Status Development Program Overview ● Drug the historically ‘undruggable’ target − KRAS G12C can be inhibited covalently • Phase 1 study − IBI351 shows the BIC potential prec
Slide 17: IBI-188 (CD47)
IBI-188 (CD47) Updated Results of Phase 1b PoC Study for MDS IBI-188 Phase 1b Study: 1L MDS Major Clinical data in high risk MDS Azacitidine + IBI188 1L MDS Azacitidine 75mg/m2 D1-D7 every cycle, 28 days one cycle Study Identifier: NCT04485065 Updated Phase 1b efficacy data from 28 patients with at
Slide 18: IBI-939 (TIGIT)
IBI-939 (TIGIT) Preliminary Efficacy Signal in PD-1 TPS>=50% NSCLC IBI-939: fully human IgG4 mAb targeting TIGIT Development Progress IBI-939 is fully human IgG4 mAb with high TIGIT binding affinity and • One of the few TIGIT programs with encouraging signal strong ligand blocking activity - Exhibit
Slide 19: IBI-322 (PDL1/CD47)
IBI-322 (PDL1/CD47) Preliminary Efficacy Signal in Lymphoma IBI-322: fully human bispecific antibody targeting CD47/PD-L1 Development Progress IBI-322 is fully human bispecific antibody with synergic • Phase 1 studies ongoing inhibition of both CD47 and PD-L1 for anti-cancer effect - China/US Phase
Slide 20: IL-2 Cluster: IBI-363 & IBI-127
IL-2 Cluster: IBI-363 (PD-1/IL2) & IBI-127 (Non-α IL2) Highly Potent PD-1/IL2 bispecific antibody Differentiated PEG Engineered IL-2 IBI-363 for IO failed patients IBI-127* for Specificity and Selectivity New ● IBI-363 maintain CD25(IL2Rɑ)activity for max efficacy & ● IBI-127 is a potential FIC with
Slide 21: Select Pipeline – Non-oncology
Divider: 换一个自己做的 Select Pipeline – Non-oncology Section 1 Business Overview - 2021
Slide 22: Tafolecimab (IBI-306, PCSK9)
Tafolecimab (IBI-306, PCSK9) Potentially First China-developed PCSK9 as NDA Accepted in June 2022 Data of Ph3 Studies (CREDIT-1 and CREDIT-2) Comparison with other PCSK9 in China IBI-306 Imported PCSK9i Percent change from baseline in Other Domestic PCSK9i Innovent Amgen, Sanofi 20 NDA accepted for
Slide 23: IBI-362 (mazdutide)
IBI-362 (mazdutide): Potentially the Best GLP-1/GCGR Molecule to Treat Obesity and Diabetes Balanced GLP-1/GCGR Dual Agonist Development Program Overview ● 2022.06 Phase 2 study in obesity data readout ● 2022.07 Phase 2 study in diabetes data readout ● At ENDO 2022 data readout for Phase 1b high-dos
Slide 24: Mazdutide: Weight Loss Effect in Phase 2 for Obesity
Mazdutide (IBI-362, GLP-1/GCGR): Proven Robust Weight Loss Effect in Phase 2 Study for Obesity 24-Week Weight Loss 11.6% at Dose Regime 2-4-6 mg 12-Week Weight Loss 11.7% at Dose Regime 3-6-9 mg Mean Body Weight Change at Week 24 The least squares (LS) mean percent change(absolute Overall mean basel
Slide 25: Mazdutide: Glycemic Control and Weight Loss in Phase 2 for Diabetes
Mazdutide (IBI-362, GLP-1/GCGR): Dual Efficacy on Glycemic Control and Weight Loss in Phase 2 for Diabetes 12 Week Proof Of Concept In Diabetes 20 Week Phase 2 Study In Diabetes IBI362 3.0 mg (n=43) HbA1c HbA1c 较基线的变化（%） reduction from baseline 100 Proportion of Participants IBI362 4.5 mg (n=43) FPG
Slide 26: IBI-302 (VEGF/Complement)
IBI-302 (VEGF/Complement) Global First-in-Class with Potential Effect in Retinal Fibrosis IBI-302 For Long Term Vision Maintaining with Global Rights IBI-302: a bispecific fusion protein targeting VEGF and complement IBI-302 has the potential to improve visual acuity & retinal edema, prevent/inhibit
Slide 27: IBI-112 (IL23p19)
IBI-112 (IL23p19) Long-dose interval and long-term efficacy as potential BIC IL23 IBI-112 MoA and Phase 2 data Long-dose interval with differentiated MoA Phase 2 for Psoriasis Efficacy: PASI 90 response rate (%) • The study results placebo 50mg q12w 100mg q12w 100mg q8w 200mg q12w • IBI-112 have an
Slide 28: IBI354 (Orismilast)
IBI354 (Orismilast) Potential Best-in-class Phase 2 PDE4 inhibitor Clinical Highlights Development Program Overview Indirect comparison from Ph2a suggests Moderate to severe Psoriasis Orismilast oral Share of Psoriasis potential to be ~50% ● Ph2b trial (ex-China lead by UNION) IND with 75% more effi
Slide 29: VEGF Cluster: IBI333 & IBI324
VEGF Cluster: IBI333 (VEGF-A/VEGF-C) & IBI324 (VEGF/ANG-2) A bispecific recombinant fully humanized A bispecific antibody targeting VEGF-A IBI333 fusion protein targeting VEGF-A and VEGF-C IBI324 and Ang2 Free VEGF A VEGFR domain2 ✱ Anti-VEGF-A scFv Inhibit neovascularization Inhibit vascular leakag
Slide 30: IBI-311 (IGF-1R)
IBI-311 (IGF-1R) Potentially Best-in-Class Profile with Clear Unmet Medical Need in China Clear and Validated MoA Clear Unmet needs for active TAO • 170K new TAOs each year in China with no approved drug • Severely affects appearance and social functioning • No effective treatment to relieve proptos
Slide 31: Key Takeaway: Robust Pipeline to Address Unmet Medical Needs
Key Takeaway: Robust Pipeline to Address Unmet Medical Needs with Huge Global Market Potential Robust Pipeline Across Novel Therapeutics Target on Unmet Medical Needs Number of new cancer cases in 2020 (Global) Number of new cancer cases in 2020 (China) High potential IO backbone : PD-1, % 11.7% 11.
Slide 32: Confidential
Confidential Copyright© 2022 Innovent 32